Dr. Hazel H. Szeto, MD, PhD
Pharmacology at Weill Cornell Medical College
Biography & Research Background
Hazel H. Szeto, MD, PhD, is a Professor in the Department of Pharmacology at Weill Cornell Medical College and co-discoverer of the Szeto-Schiller (SS) class of mitochondria-targeted peptides, including SS-31 (elamipretide). Her laboratory identified that SS-31 selectively binds cardiolipin on the inner mitochondrial membrane, thereby optimizing electron transport and restoring cellular bioenergetics in disease states. She co-founded Stealth Peptides (now Stealth BioTherapeutics) to advance elamipretide into clinical development. Key publications: 'First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics' (British Journal of Pharmacology, 2014) and extensive preclinical characterization of SS peptide pharmacology. Dr. Szeto's work provided the scientific foundation for the FDA's 2025 Accelerated Approval of Forzinity™ for Barth syndrome. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
External Profiles
Authored Research Profiles (1)
Dr. Hazel H. Szeto, MD, PhD is referenced as a leading researcher in the following peptide research profiles on Pure U.S. Peptides:
Dr. Hazel H. Szeto, MD, PhD is being referenced as one of the leading scientists involved in the research and development of the peptides listed above. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of any product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure U.S. Peptides and this researcher. The purpose of citing the researcher is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying these peptides.